Anemia in CKD Patients
Conditions
Brief summary
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD
Interventions
DRUGSGLT2 inhibitor
prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1\_4
Sponsors
Sohag University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* age more than 18 years * CKD stage 1\_4 * baseline hemoglobin 8.5 to 12.9 g/dl * stable anemia regimen for more than 8 weeks
Exclusion criteria
* dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| hemoglobin level | 12 weeks | use the hemoglobin level to assist the effect of SGLT2 inhibitors On anemia correction |
| change in hemoglobin level | 12 weeks | anemia correction |
Countries
Egypt
Contacts
Primary ContactRomany Naguib Mikhaeil, master
Backup ContactAhmed Nagah NourEldin, associate professor
Outcome results
None listed